Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.German pharmaceutical company Boehringer Ingelheim has selected the Medidata Clinical Cloud platform to speed up innovation in its drug development programs.
Subscribe to our email newsletter
Medidata’s technology platform will allow the pharmaceutical firm to carry out faster and more accurate clinical trials.
The study planning, data management, data analytics and risk-based monitoring (RBM) capabilities of Medidata will be integrated into several stages of Boehringer Ingelheim’s drug development process.
Boehringer Ingelheim is implementing the Medidata Clinical Cloud platform and several of the technology firm’s solutions to improve its portfolio of phase I-III and post-approval trials.
The company will also use Medidata Insights, which is claimed to offer advanced metrics, visualizations and the most powerful set of industry data and benchmarks. A phased rollout is due to start next year.
Boehringer Ingelheim will also adopt solutions within Medidata risk-based monitoring including Medidata TSDV and Medidata SQM to better prioritize resources on patient safety, data quality and integrity.
Medidata CEO Tarek Sherif said: "Our cloud technology and data-driven analytics deliver the features, the scale and the precise insights that Boehringer Ingelheim and a rapidly growing list of other global pharma companies need to develop exciting medical advances to improve people’s health and transform their lives."
Boehringer Ingelheim global head of biostatistics & data sciences Klaus Stern said: "Medidata’s platform of cloud-based solutions and data analytics will increase the efficiency of our R&D and help us be more nimble in developing and conducting increasingly complex clinical trials."
Image: Boehringer Ingelheim biopharmaceuticals production plant in Europe. Photo: courtesy of Boehringer Ingelheim GmbH.